Snapshot from Sep 18, 2026 at 07:00 UTC. For live data and tracking: View Live
Business conference participation

Compass Pathways at Cantor Healthcare Conference

Analysis based on 6 articles · First reported Sep 01, 2026 · Last updated Sep 01, 2026

Sentiment
0
Attention
0
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The announcement is a routine corporate communication with minimal direct market impact. It may modestly increase visibility for Compass Pathways among investors attending the conference, but no material financial or operational changes are expected.

Biotechnology Mental Health

Compass Pathways plc announced that its management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026, participating in a fireside chat at 3:20pm ET and a panel titled 'PSYCH! Accessing The New Wave of Psychedelics' at 4:30pm ET. The company is developing COMP360, an investigational synthetic psilocybin treatment for treatment-resistant depression and post-traumatic stress disorder, which has received Breakthrough Therapy designation from the United States — Food and Drug Administration and Innovative Licensing and Access Pathway designation in the United Kingdom. The event provides a platform for Compass Pathways to present its clinical programs and engage with investors and industry peers.

20 Compass Pathways announced attendance
stock
Compass Pathways is the subject of the announcement, participating in the conference to present its psychedelic treatment programs. The event is a routine investor relations activity with no expected impact on its stock price.
Importance 100.0 Sentiment 0.0
oth
The conference serves as the venue for Compass Pathways' presentations, providing a platform for healthcare companies to engage with investors. The event itself is not directly affected by this participation.
Importance 50.0 Sentiment 0.0
govactor
The FDA granted Breakthrough Therapy designation to COMP360, a fact mentioned in the announcement. This designation is a regulatory milestone but is not the focus of the event.
Importance 20.0 Sentiment 0.0
cnt
The United States is the location of the conference and the FDA, but the event has no direct impact on the country.
Importance 10.0 Sentiment 0.0
cnt
The United Kingdom granted Innovative Licensing and Access Pathway designation for COMP360, mentioned as background. No direct impact from the conference participation.
Importance 10.0 Sentiment 0.0
loc
United Kingdom — London is the headquarters of Compass Pathways, mentioned in the company description. No direct impact from the event.
Importance 5.0 Sentiment 0.0
loc
United States — New York City is the location of Compass Pathways' U.S. office, mentioned in the company description. No direct impact from the event.
Importance 5.0 Sentiment 0.0
United States allies ↔ United Kingdom The United States considers the United Kingdom a vital defense ally and significant economic partner, relying on its str
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.